Version: 1.0.0 | Published: 31 Aug 2026 | Updated: 1 day ago
Documentation
Description:
The TRAP trial tested whether stereotactic body radiotherapy (SBRT) could slow down the growth of prostate cancer, in men who had developed one or two new sites of worsening (growing) disease, despite being on treatment (Abiraterone or Enzalutamide) to which the rest of their cancer is still responding.
Standard treatment in this population is hormone therapy followed by chemotherapy on progression - however chemotherapy has unwanted side-effects and does not offer long-term control.
SBRT is a recognised technique for the elimination of isolated metastases in other tumour sites achieving local control of metastasis in 80-90% of cases. SBRT destroys cancerous tissue irrespective of the underlying genetic deficit within the progressing metastasis - so the logic was that if the resistant clones were localized to 1-2 metastases and could be destroyed or ablated, the patient could continue to receive the benefit of their systemic (androgen deprivation) treatment.
However it was expected that SBRT would be more effective in some men than others, so the study also looked at circulating tumour deoxyribonucleic acid (ctDNA) in blood to identify the biomarkers released into the bloodstream by the metasteses (comparing findings with previously explored genome mutations in prostate cancer patients), and at characteristics from imaging using whole bodydiffusion weighted magnetic resonance imaging (WB-DW-MRI)- a novel MRI technique which shows improved sensitivity compared to standard MRI - to look for patterns that might identify future patients who might benefit most from this approach.
Coverage
Spatial:
United Kingdom
Typical Age Range:
18-150
Follow Up:
Other
Pathway:
We identified men who, despite being on next generation androgen deprivation
treatment (Abiraterone or Enzalutamide) had developed one or two new sites of
worsening (growing) disease but the rest of their cancer still appeared to be
responding to hormonal therapy. Patients enrolled on the trial received 30 Gy in
5 fractions on alternate days over 10 days, while continuing their androgen
deprivation treatment throughout and following SBRT. Side effects were closely
monitored throughout and participants were seen at the end of radiotherapy and
then 4 weeks after treatment. Thereafter participants were followed up every
three months including Prostate Specific Antigen (PSA) monitoring. In addition
to the above procedures, participants underwent whole body (WB) diffusion
weighted (DW) magnetic resonance imaging (WB DW MRI) and blood samples were
taken to assess circulating tumour (ct) deoxyribonucleic acid (DNA).
Provenance
Origin
Purposes:
Trial
Sources:
- Other
- Machine generated
Collection Situations:
Cohort, study, trial
Temporal
Accrual Periodicity:
Static
Start Date:
09 August 2018
End Date:
31 March 2025
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
in progress - for now contact RM via email given, sample status unconfirmed (but held via UCL)
Access Service:
Although not required, there is an option to use The Royal Marsden’s Trusted
Research Environment and informatics platform: BRIDgE (Biomedical Research
Informatics Digital Environment). BRIDgE is managed by The Royal Marsden’s
Information Team with support by the NIHR Biomedical Research Centre at The
Royal Marsden and ICR. The aim of the platform is to transform clinical practice
and improve outcomes for patients by enabling researchers to access real-world
cancer data within secure, collaborative, cloud-based workspaces. Learn more by
visiting the BRIDgE site within the NIHR BRC area of The Royal Marsden and ICR
website: https://www.cancerbrc.org/BRIDgE
Access Request Cost:
Depends on type of access. Costing available on application.
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
Royal Marsden NHS Foundation Trust
Data Processor:
Royal Marsden NHS Foundation Trust
Usage
Data Use Limitations:
Research-specific restrictions
Data Use Requirements:
- Ethics approval required
- Institution-specific restrictions
- User-specific restriction
- Not for profit use
Resource Creators:
The Royal Marsden NHS Foundation Trust;
The Royal Marsden Cancer Charity;
NIHR Biomedical Research Centre at The Royal Marsden and the ICR;
Prostate Cancer UK
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en